

Daniel J. MÃ¼ller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9564561/publications.pdf>

Version: 2024-02-01

271
papers

12,865
citations

24978

57
h-index

34900

98
g-index

283
all docs

283
docs citations

283
times ranked

12362
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , 2022, 32, 1223-1243.	1.6	6
2	Perspectives on the Clinical Use of Pharmacogenetic Testing in Late-Life Mental Healthcare: A Survey of the American Association of Geriatric Psychiatry Membership. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 560-571.	0.6	3
3	Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. <i>Molecular Psychiatry</i> , 2022, 27, 593-605.	4.1	13
4	Encountering Pharmacogenetic Test Results in the Psychiatric Clinic. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 95-100.	0.9	4
5	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	1.3	3
6	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. <i>Translational Psychiatry</i> , 2022, 12, 101.	2.4	17
7	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	1.7	107
8	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	4.1	44
9	Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210965.	1.2	17
10	Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2022, 22, 230-240.	0.9	8
11	Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study. <i>Pharmaceuticals</i> , 2022, 15, 870.	1.7	10
12	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110194.	2.5	11
13	Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 1019-1041.	0.9	4
14	The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. <i>European Journal of Nutrition</i> , 2021, 60, 2905-2921.	1.8	25
15	Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia. <i>Drug Development Research</i> , 2021, 82, 678-684.	1.4	5
16	Older molecular brain age in severe mental illness. <i>Molecular Psychiatry</i> , 2021, 26, 3646-3656.	4.1	23
17	Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia. <i>Journal of Psychopharmacology</i> , 2021, 35, 31-39.	2.0	5
18	Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 231-255.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. <i>Translational Psychiatry</i> , 2021, 11, 127.	2.4	22
20	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. <i>Frontiers in Psychiatry</i> , 2021, 12, 617997.	1.3	32
21	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i> , <i>OPRM1</i> , and <i>COMT</i> Genotypes and Select Opioid Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 888-896.	2.3	212
22	The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment. <i>Nutrients</i> , 2021, 13, 1152.	1.7	25
23	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>CNS Drugs</i> , 2021, 35, 291-304.	2.7	4
24	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. <i>Pharmacopsychiatry</i> , 2021, 54, 225-231.	1.7	1
25	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. <i>CNS Drugs</i> , 2021, 35, 439-450.	2.7	4
26	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. <i>PLoS ONE</i> , 2021, 16, e0253023.	1.1	4
27	Economic evaluation in psychiatric pharmacogenomics: a systematic review. <i>Pharmacogenomics Journal</i> , 2021, 21, 533-541.	0.9	28
28	Exploring brain connectivity changes in major depressive disorder using functional-structural data fusion: A CAN-BIND-1 study. <i>Human Brain Mapping</i> , 2021, 42, 4940-4957.	1.9	8
29	A systematic review on neuromodulation therapies for reducing body weight in patients with obesity. <i>Obesity Reviews</i> , 2021, 22, e13309.	3.1	11
30	Changes in RNA expression levels during antidepressant treatment: a systematic review. <i>Journal of Neural Transmission</i> , 2021, 128, 1461-1477.	1.4	1
31	Pharmacogenetics-Guided Advances in Antipsychotic Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 582-588.	2.3	12
32	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. <i>Translational Psychiatry</i> , 2021, 11, 439.	2.4	3
33	Association between the expression of lncRNA <i>BASP-AS1</i> and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. <i>Translational Psychiatry</i> , 2021, 11, 469.	2.4	1
34	The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study. <i>JMIR Research Protocols</i> , 2021, 10, e31439.	0.5	5
35	Reviewing pharmacogenetics to advance precision medicine for opioids. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112060.	2.5	14
36	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. <i>Psychoneuroendocrinology</i> , 2021, 132, 105348.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 5-17.	1.7	96
38	Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. <i>Pharmacopsychiatry</i> , 2021, 54, 81-89.	1.7	7
39	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. <i>NeuroImage: Clinical</i> , 2021, 32, 102864.	1.4	13
40	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 2742-2751.	2.7	38
41	Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1334.	1.1	16
42	Investigation of the Gut Microbiome in Patients with Schizophrenia and Clozapine-Induced Weight Gain: Protocol and Clinical Characteristics of First Patient Cohorts. <i>Neuropsychobiology</i> , 2020, 79, 5-12.	0.9	11
43	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2020, 50, 2536-2547.	2.7	17
44	From the Origins of Pharmacogenetics to First Applications in Psychiatry. <i>Pharmacopsychiatry</i> , 2020, 53, 155-161.	1.7	17
45	Opportunities and challenges of implementation models of pharmacogenomics in clinical practice. , 2020, , 449-457.		0
46	Genetic testing in psychiatry: State of the evidence. , 2020, , 437-448.		0
47	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 921-932.	1.8	22
48	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 88-95.	1.0	12
49	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , 2020, 264, 414-424.	2.0	6
50	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. <i>Human Brain Mapping</i> , 2020, 41, 1400-1415.	1.9	7
51	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , 2020, 11, 575540.	1.6	46
52	Liver enzyme <i>CYP2D6</i> gene and tardive dyskinesia. <i>Pharmacogenomics</i> , 2020, 21, 1065-1072.	0.6	4
53	Regulation of melanocortin-4-receptor (MC4R) expression by SNP rs17066842 is dependent on glucose concentration. <i>European Neuropsychopharmacology</i> , 2020, 37, 39-48.	0.3	3
54	Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial. <i>Frontiers in Public Health</i> , 2020, 8, 391.	1.3	1

#	ARTICLE	IF	CITATIONS
55	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 521-530.	0.9	32
56	Validation study of microRNAs previously associated with antidepressant response in older adults treated for late-life depression with venlafaxine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 100, 109867.	2.5	8
57	Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 609-629.	0.6	18
58	Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109952.	2.5	8
59	Ketamine Treatment in Depression: A Systematic Review of Clinical Characteristics Predicting Symptom Improvement. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1398-1414.	1.0	4
60	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , 2020, 17, 30-40.	0.1	6
61	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. <i>Journal of Affective Disorders</i> , 2019, 257, 765-773.	2.0	20
62	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. <i>Translational Psychiatry</i> , 2019, 9, 254.	2.4	33
63	Towards precision medicine in generalized anxiety disorder: Review of genetics and pharmaco(epi)genetics. <i>Journal of Psychiatric Research</i> , 2019, 119, 33-47.	1.5	19
64	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. <i>Schizophrenia Research</i> , 2019, 212, 204-212.	1.1	15
65	Towards pharmacogenetic-based treatment in psychiatry. <i>Journal of Neural Transmission</i> , 2019, 126, 1-3.	1.4	7
66	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109659.	2.5	9
67	The coming of age of pharmacogenetic testing in clinical psychiatry. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 203-203.	1.0	1
68	Navigating the Labyrinth of Pharmacogenetic Testing: A Guide to Test Selection. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 309-312.	2.3	38
69	Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole. <i>Journal of Psychiatric Research</i> , 2019, 114, 67-74.	1.5	3
70	Genome-Wide Association Study of Sleep Disturbances in Depressive Disorders. <i>Molecular Neuropsychiatry</i> , 2019, 5, 34-43.	3.0	1
71	Association Study of the Complement Component C4 Gene in Tardive Dyskinesia. <i>Frontiers in Pharmacology</i> , 2019, 10, 1339.	1.6	11
72	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2019, 49, 1629-1638.	2.7	22

#	ARTICLE	IF	CITATIONS
73	Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature. <i>Journal of Neural Transmission</i> , 2019, 126, 65-85.	1.4	16
74	Towards the integration of pharmacogenetics in psychiatry. <i>Current Opinion in Psychiatry</i> , 2019, 32, 7-15.	3.1	103
75	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. <i>Journal of Neural Transmission</i> , 2019, 126, 27-33.	1.4	13
76	Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications. <i>Molecular Neuropsychiatry</i> , 2019, 5, 1-26.	3.0	30
77	Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication. <i>Psychiatry Research</i> , 2019, 279, 111-115.	1.7	33
78	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 91-95.	1.3	8
79	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 223-236.	1.4	37
80	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	61
81	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	16
82	Affectively Biased Competition: Sustained Attention is Tuned to Rewarding Expressions and is Not Modulated by Norepinephrine Receptor Gene Variant. <i>Collabra: Psychology</i> , 2019, 5, .	0.9	0
83	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 99, 62-68.	1.5	60
84	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
85	Genetic testing as a supporting tool in prescribing psychiatric medication: Design and protocol of the IMPACT study. <i>Journal of Psychiatric Research</i> , 2018, 96, 265-272.	1.5	28
86	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2018, 19, S97-S105.	1.3	11
87	The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 3-15.	1.8	67
88	Genome-wide association studies of placebo and duloxetine response in major depressive disorder. <i>Pharmacogenomics Journal</i> , 2018, 18, 406-412.	0.9	17
89	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. <i>Journal of Affective Disorders</i> , 2018, 227, 542-549.	2.0	59
90	Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life. <i>Pharmacogenomics</i> , 2018, 19, 1269-1284.	0.6	16

#	ARTICLE	IF	CITATIONS
91	Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 974.	1.6	17
92	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 214-222.	0.7	57
93	Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based Care. <i>JAMA Psychiatry</i> , 2018, 75, 1090.	6.0	5
94	Pharmacogenetic evaluation of a <i>DISP1</i> gene variant in antidepressant treatment of obsessive-compulsive disorder. <i>Human Psychopharmacology</i> , 2018, 33, e2659.	0.7	7
95	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. <i>Neuroscience Letters</i> , 2018, 686, 17-22.	1.0	7
96	Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults. <i>American Journal of Psychiatry</i> , 2017, 174, 468-475.	4.0	41
97	Association study between the neurexin-1 gene and tardive dyskinesia. <i>Human Psychopharmacology</i> , 2017, 32, e2568.	0.7	9
98	Cognitive and psychosocial function in retired professional hockey players. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 512-519.	0.9	51
99	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , 2017, 8, 15497.	5.8	144
100	Clinical pharmacogenetics implementation consortium guideline (CPIC) for <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and dosing of tricyclic antidepressants: 2016 update. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 37-44.	2.3	450
101	Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 1-6.	0.7	12
102	C-reactive protein and cardiovascular risk in bipolar disorder patients: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 442-451.	2.5	24
103	A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain. <i>Schizophrenia Research</i> , 2017, 187, 67-73.	1.1	18
104	Verbal memory improvement in first-episode psychosis & APOE-ε4 carriers: a pleiotropic effect?. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2945-2953.	1.0	6
105	The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. <i>Frontiers in Neuroscience</i> , 2017, 11, 741.	1.4	78
106	Low-Dose Lithium Stabilizes Human Endothelial Barrier by Decreasing MLC Phosphorylation and Universally Augments Cholinergic Vasorelaxation Capacity in a Direct Manner. <i>Frontiers in Physiology</i> , 2016, 7, 593.	1.3	25
107	The role of the ITIH3 rs2535629 variant in antipsychotic response. <i>Schizophrenia Research</i> , 2016, 176, 131-135.	1.1	23
108	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 172-185.	2.3	146

#	ARTICLE	IF	CITATIONS
109	Molecular mechanisms in lithium-associated renal disease: a systematic review. <i>International Urology and Nephrology</i> , 2016, 48, 1843-1853.	0.6	18
110	Genetics of Common Antipsychotic-Induced Adverse Effects. <i>Molecular Neuropsychiatry</i> , 2016, 2, 61-78.	3.0	47
111	Childhood Abuse History in Depression Predicts Better Response to Antidepressants with Higher Serotonin Transporter Affinity: A Pilot Investigation. <i>Neuropsychobiology</i> , 2016, 74, 78-83.	0.9	15
112	A differential impact of lithium on endothelium-dependent but not on endothelium-independent vessel relaxation. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 67, 98-106.	2.5	23
113	Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample. <i>Pharmacogenomics Journal</i> , 2016, 16, 352-356.	0.9	37
114	Pharmacogenetics of tardive dyskinesia: an updated review of the literature. <i>Pharmacogenomics</i> , 2016, 17, 1339-1351.	0.6	38
115	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 540-560.	0.9	746
116	Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. <i>Molecular Neuropsychiatry</i> , 2016, 2, 1-14.	3.0	47
117	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. <i>Molecular Neuropsychiatry</i> , 2016, 2, 185-197.	3.0	14
118	Association Study of Serotonin 3 Receptor Subunit Gene Variants in Antipsychotic-Induced Weight Gain. <i>Neuropsychobiology</i> , 2016, 74, 169-175.	0.9	4
119	Genetic association analysis of N-methyl-D-aspartate receptor subunit gene <i>GRIN2B</i> and clinical response to clozapine. <i>Human Psychopharmacology</i> , 2016, 31, 121-134.	0.7	19
120	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , 2016, 16, 105.	1.1	114
121	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv132.	1.0	50
122	Preliminary evidence for association of genome-wide significant <i>DRD2</i> schizophrenia risk variant with clozapine response. <i>Pharmacogenomics</i> , 2016, 17, 103-109.	0.6	37
123	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 221-229.	1.3	24
124	Pharmacogenetics of Serious Antipsychotic Side Effects. , 2016, , 21-38.		0
125	Linking unfounded beliefs to genetic dopamine availability. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 521.	1.0	12
126	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and <i>CYP2C19</i> Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 127-134.	2.3	739

#	ARTICLE	IF	CITATIONS
127	Physicians' opinions following pharmacogenetic testing for psychotropic medication. <i>Psychiatry Research</i> , 2015, 229, 913-918.	1.7	51
128	Investigation of <i>TSPO</i> variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , 2015, 16, 5-22.	0.6	15
129	The role of genetic variation across <i>IL-1β</i> , <i>IL-2</i> , <i>IL-6</i> , and <i>BDNF</i> in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 45-56.	1.3	28
130	The Effects of Video Games on Cognition and Brain Structure: Potential Implications for Neuropsychiatric Disorders. <i>Current Psychiatry Reports</i> , 2015, 17, 71.	2.1	45
131	Neurogenetic Variations in Norepinephrine Availability Enhance Perceptual Vividness. <i>Journal of Neuroscience</i> , 2015, 35, 6506-6516.	1.7	86
132	Genetic variation in <i>CYP3A43</i> is associated with response to antipsychotic medication. <i>Journal of Neural Transmission</i> , 2015, 122, 29-34.	1.4	25
133	Personalized therapies in psychiatry: promises, pitfalls and perspectives. <i>Journal of Neural Transmission</i> , 2015, 122, 1-3.	1.4	9
134	Association Study of <i>GABAAβ2</i> Receptor Subunit Gene Variants in Antipsychotic-Associated Weight Gain. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 7-12.	0.7	18
135	Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction". <i>Current Psychiatry Reports</i> , 2015, 17, 96.	2.1	40
136	Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1709-1731.	1.5	31
137	Genetic variation in <i>IL-1β</i> , <i>IL-2</i> , <i>IL-6</i> , <i>TSPO</i> and <i>BDNF</i> and response to duloxetine or placebo treatment in major depressive disorder. <i>Pharmacogenomics</i> , 2015, 16, 1919-1929.	0.6	19
138	The uncanny return of the race concept. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 836.	1.0	37
139	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	0.7	341
140	Genetic variation in the <i>GCG</i> and in the <i>GLP1R</i> genes and antipsychotic-induced weight gain. <i>Pharmacogenomics</i> , 2014, 15, 423-431.	0.6	12
141	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. <i>Neuropsychopharmacology</i> , 2014, 39, 1347-1354.	2.8	26
142	Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis. <i>Molecular Psychiatry</i> , 2014, 19, 403-405.	4.1	20
143	Second Generation Antipsychotic-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Review of the Experimental Literature. <i>Current Psychiatry Reports</i> , 2014, 16, 510.	2.1	61
144	Fat Mass- and Obesity-Associated (<i>FTO</i>) Gene and Antipsychotic-Induced Weight Gain: An Association Study. <i>Neuropsychobiology</i> , 2014, 69, 59-63.	0.9	16

#	ARTICLE	IF	CITATIONS
145	Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. <i>Pharmacogenomics Journal</i> , 2014, 14, 176-181.	0.9	56
146	Protein kinase cAMP-dependent regulatory type II beta (<i>PRKAR2B</i>) gene variants in antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , 2014, 29, 330-335.	0.7	10
147	Mitotic Cell Shape - RNA Interference Screening for Genes Involved in Mechanics using Atomic Force Microscopy. <i>Biophysical Journal</i> , 2014, 106, 787a.	0.2	0
148	Deletion variant in the ADRA2B gene increases coupling between emotional responses at encoding and later retrieval of emotional memories. <i>Neurobiology of Learning and Memory</i> , 2014, 112, 222-229.	1.0	60
149	Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. <i>Pharmacogenomics</i> , 2014, 15, 1147-1157.	0.6	41
150	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 404-410.	1.3	17
151	Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed. <i>Current Psychiatry Reports</i> , 2014, 16, 473.	2.1	68
152	Investigation of melanocortin system gene variants in antipsychotic-induced weight gain. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 251-258.	1.3	5
153	Pharmacogenomic Testing for Neuropsychiatric Drugs: Current Status of Drug Labeling, Guidelines for Using Genetic Information, and Test Options. <i>Pharmacotherapy</i> , 2014, 34, 166-184.	1.2	69
154	Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1434-1441.	1.3	43
155	Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. <i>Journal of Psychiatric Research</i> , 2014, 54, 36-42.	1.5	26
156	Role of synaptosome-related (SNARE) genes in adults with attention deficit hyperactivity disorder. <i>Psychiatry Research</i> , 2014, 215, 799-800.	1.7	8
157	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. <i>Psychiatry Research</i> , 2014, 219, 255-260.	1.7	13
158	Pharmacogenetics of Antipsychotics. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 76-88.	0.9	83
159	Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight. <i>Translational Developmental Psychiatry</i> , 2014, 2, 24663.	0.3	7
160	Pharmacogenetics of Antipsychotic Treatment in Schizophrenia. <i>Methods in Molecular Biology</i> , 2014, 1175, 557-587.	0.4	20
161	Pharmacogenetics and outcome with antipsychotic drugs. <i>Dialogues in Clinical Neuroscience</i> , 2014, 16, 555-566.	1.8	72
162	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 324-328.	2.3	237

#	ARTICLE	IF	CITATIONS
163	Genes for Emotion-Enhanced Remembering Are Linked to Enhanced Perceiving. <i>Psychological Science</i> , 2013, 24, 2244-2253.	1.8	116
164	Future roles of pharmacogenomic testing and Biomarkers in Psychiatry. <i>International Review of Psychiatry</i> , 2013, 25, 493-493.	1.4	3
165	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. <i>Journal of Psychiatric Research</i> , 2013, 47, 1760-1765.	1.5	55
166	Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 402-408.	2.3	397
167	Towards the implementation of <i>CYP2D6</i> and <i>CYP2C19</i> genotypes in clinical practice: Update and report from a pharmacogenetic service clinic. <i>International Review of Psychiatry</i> , 2013, 25, 554-571.	1.4	63
168	Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: A case-control study. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 500-508.	1.3	84
169	Analysis of 34 candidate genes in bupropion and placebo remission. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 771-781.	1.0	34
170	The pharmacogenetics of antipsychotic-induced adverse events. <i>Current Opinion in Psychiatry</i> , 2013, 26, 144-150.	3.1	44
171	KIBRA Polymorphism Is Associated with Individual Differences in Hippocampal Subregions: Evidence from Anatomical Segmentation using High-Resolution MRI. <i>Journal of Neuroscience</i> , 2013, 33, 13088-13093.	1.7	51
172	Association of a Functional Polymorphism in Neuropeptide Y With Antipsychotic-Induced Weight Gain in Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 11-17.	0.7	44
173	Exploratory study on association of genetic variation in <i>TBC1D1</i> with antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , 2013, 28, 183-187.	0.7	14
174	The influence of dopamine-related genes on perceptual stability. <i>European Journal of Neuroscience</i> , 2013, 38, 3378-3383.	1.2	19
175	Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. <i>Pharmacogenomics Journal</i> , 2013, 13, 272-279.	0.9	49
176	Genetics of antipsychotic-induced weight gain: update and current perspectives. <i>Pharmacogenomics</i> , 2013, 14, 2067-2083.	0.6	38
177	Genetics and Personalized Medicine in Antidepressant Treatment. <i>Current Pharmaceutical Design</i> , 2012, 18, 5853-5878.	0.9	21
178	Association of the <i>MTHFR</i> gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. <i>Pharmacogenomics</i> , 2012, 13, 843-846.	0.6	10
179	Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. <i>Pharmacogenomics Journal</i> , 2012, 12, 260-266.	0.9	26
180	Editorial (Hot Topic :Treatment with Antidepressants). <i>Current Pharmaceutical Design</i> , 2012, 18, 5789-5790.	0.9	1

#	ARTICLE	IF	CITATIONS
181	Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , 2012, 12, 156-164.	0.9	54
182	Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 38, 134-141.	2.5	65
183	Association Between Common Variants Near the Melanocortin 4 Receptor Gene and Severe Antipsychotic Drug-Induced Weight Gain. <i>Archives of General Psychiatry</i> , 2012, 69, 904.	13.8	165
184	The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 96-101.	2.5	61
185	Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. <i>Molecular Psychiatry</i> , 2012, 17, 242-266.	4.1	225
186	The AmpliChip [®] CYP450 Test and Response to Treatment in Schizophrenia and Obsessive Compulsive Disorder: A Pilot Study and Focus on Cases with Abnormal CYP2D6 Drug Metabolism. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 897-903.	0.3	29
187	Pharmacogenetics of obsessive-compulsive disorders. <i>Pharmacogenomics</i> , 2012, 13, 71-81.	0.6	32
188	Association between Oxytocin Receptor Gene Polymorphisms and Self-Rated "Empathic Concern" in Schizophrenia. <i>PLoS ONE</i> , 2012, 7, e51882.	1.1	69
189	Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. <i>Journal of Psychiatric Research</i> , 2012, 46, 462-468.	1.5	26
190	ANK3, CACNA1C and ZNF804A gene variants in bipolar disorders and psychosis subphenotype. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 392-397.	1.3	41
191	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. <i>Schizophrenia Research</i> , 2011, 132, 121-124.	1.1	24
192	Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, 4, 83.	0.4	28
193	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 906-910.	0.7	77
194	Pharmacogenetics of alcohol, nicotine and drug addiction treatments. <i>Addiction Biology</i> , 2011, 16, 357-376.	1.4	61
195	Association between the DAOA/G72 gene and bipolar disorder and meta-analyses in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2011, 13, 198-207.	1.1	33
196	Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. <i>Pharmacogenomics</i> , 2011, 12, 277-291.	0.6	22
197	Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. <i>Human Psychopharmacology</i> , 2011, 26, 386-391.	0.7	10
198	Imaging and Quantifying Chemical and Physical Properties of Native Proteins at Molecular Resolution by Force-Volume AFM. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 12103-12108.	7.2	90

#	ARTICLE	IF	CITATIONS
199	Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders. <i>PLoS ONE</i> , 2011, 6, e20982.	1.1	58
200	Correlation of a set of gene variants, life events and personality features on adult ADHD severity. <i>Journal of Psychiatric Research</i> , 2010, 44, 598-604.	1.5	25
201	Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. <i>Human Psychopharmacology</i> , 2010, 25, 253-259.	0.7	30
202	Polymorphisms of the <i>HTR2C</i> gene and antipsychotic-induced weight gain: an update and meta-analysis. <i>Pharmacogenomics</i> , 2010, 11, 1561-1571.	0.6	99
203	Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 62-72.	1.0	60
204	A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 1315-1324.	2.8	95
205	Neural Markers of Genetic Vulnerability to Drug Addiction. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 3, 277-299.	0.8	17
206	Association of <i>HTR2C</i> , but not <i>LEP</i> or <i>INSIG2</i> , genes with antipsychotic-induced weight gain in a German sample. <i>Pharmacogenomics</i> , 2010, 11, 773-780.	0.6	71
207	The catechol-O-methyl-transferase gene in tardive dyskinesia. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 803-812.	1.3	25
208	Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. <i>Pharmacogenomics Journal</i> , 2010, 10, 200-218.	0.9	64
209	Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinone oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 50-56.	2.5	51
210	Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1484-1490.	2.5	18
211	Association of the α 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. <i>Pharmacogenomics</i> , 2009, 10, 1169-1176.	0.6	48
212	Pharmacogenetics of anxiolytic drugs. <i>Journal of Neural Transmission</i> , 2009, 116, 667-677.	1.4	39
213	Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. <i>Pharmacogenomics Journal</i> , 2009, 9, 168-174.	0.9	29
214	Association study of the gamma-aminobutyric acid type a receptor γ 2 subunit gene with schizophrenia. <i>Schizophrenia Research</i> , 2009, 114, 33-38.	1.1	12
215	Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. <i>European Neuropsychopharmacology</i> , 2009, 19, 317-328.	0.3	45
216	The intersection of pharmacology, imaging, and genetics in the development of personalized medicine. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 363-376.	1.8	18

#	ARTICLE	IF	CITATIONS
217	Serotonin transporter gene and adverse life events in adult ADHD. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1461-1469.	1.1	41
218	Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. <i>Schizophrenia Research</i> , 2008, 106, 248-252.	1.1	24
219	Functional Cortical Effects of Novel Allelic Variants of the Serotonin Transporter Gene-linked Polymorphic Region (5-HTTLPR) in Humans. <i>Pharmacopsychiatry</i> , 2007, 40, 191-195.	1.7	8
220	Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 639-51.	1.0	64
221	Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 697-704.	1.0	105
222	Molecular Mechanisms of Schizophrenia. <i>Cellular Physiology and Biochemistry</i> , 2007, 20, 687-702.	1.1	243
223	Further evidence of MAO-A gene variants associated with bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 37-40.	1.1	17
224	HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. <i>Human Psychopharmacology</i> , 2007, 22, 463-467.	0.7	39
225	Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. <i>Molecular Psychiatry</i> , 2007, 12, 794-795.	4.1	78
226	GENETIC RESEARCH WITH INTERMEDIATE PHENOTYPES: PHENOCOPIES, PERSPECTIVES AND PITFALLS. <i>Addiction</i> , 2007, 102, 1696-1697.	1.7	5
227	Disturbed frontal gyrfication within families affected with schizophrenia. <i>Journal of Psychiatric Research</i> , 2007, 41, 805-813.	1.5	59
228	Association analyses of the DAOA/G30 and d-amino-acid oxidase genes in schizophrenia: Further evidence for a role in schizophrenia. <i>NeuroMolecular Medicine</i> , 2007, 9, 169-177.	1.8	47
229	Genetics of antipsychotic treatment emergent weight gain in schizophrenia. <i>Pharmacogenomics</i> , 2006, 7, 863-887.	0.6	139
230	Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. <i>Psychiatry Research</i> , 2006, 141, 123-128.	1.7	27
231	Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder. <i>British Journal of Psychiatry</i> , 2006, 189, 317-323.	1.7	101
232	No evidence for association between NOTCH4 and schizophrenia in a large family-based and case-control association analysis. <i>Psychiatric Genetics</i> , 2006, 16, 197-203.	0.6	6
233	Family and case-control association study of the tumor necrosis factor-alpha (TNF- α) gene with schizophrenia and response to antipsychotic medication. <i>Psychopharmacology</i> , 2006, 188, 171-182.	1.5	48
234	Gene-gene interaction between MAOA and COMT in suicidal behavior: Analysis in schizophrenia. <i>Brain Research</i> , 2006, 1097, 26-30.	1.1	42

#	ARTICLE	IF	CITATIONS
235	Relation between cerebrospinal fluid, gray matter and white matter changes in families with schizophrenia. <i>Journal of Psychiatric Research</i> , 2006, 40, 646-655.	1.5	15
236	Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. <i>Psychopharmacology</i> , 2005, 181, 179-187.	1.5	90
237	Suggestive association between the C825T polymorphism of the G-protein $\beta 3$ subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2005, 15, 525-531.	0.3	59
238	Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics. <i>European Psychiatry</i> , 2005, 20, 65-69.	0.1	22
239	The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. <i>Neuroscience Letters</i> , 2005, 379, 81-89.	1.0	93
240	Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. <i>Pharmacological Research</i> , 2005, 51, 381-384.	3.1	8
241	Evidence of Association between Smoking and $\alpha 7$ Nicotinic Receptor Subunit Gene in Schizophrenia Patients. <i>Neuropsychopharmacology</i> , 2004, 29, 1522-1526.	2.8	129
242	Etiopathogenetic Mechanisms in Long-Term Course of Schizophrenia. <i>Pharmacopsychiatry</i> , 2004, 37, 136-140.	1.7	6
243	Analysis of the novel TPH2 gene in bipolar disorder and suicidality. <i>Molecular Psychiatry</i> , 2004, 9, 896-897.	4.1	58
244	Clinical implications of pharmacogenomics for tardive dyskinesia. <i>Pharmacogenomics Journal</i> , 2004, 4, 77-87.	0.9	52
245	Pharmacogenetics of antipsychotic-induced weight gain. <i>Pharmacological Research</i> , 2004, 49, 309-329.	3.1	69
246	Genetics of schizophrenia: current strategies. <i>Clinical Neuroscience Research</i> , 2003, 3, 5-16.	0.8	6
247	Overview: Towards individualized treatment in schizophrenia. <i>Drug Development Research</i> , 2003, 60, 75-94.	1.4	9
248	Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. <i>American Journal of Medical Genetics Part A</i> , 2003, 119B, 35-39.	2.4	43
249	CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients. <i>Pharmacopsychiatry</i> , 2003, 36, 73-78.	1.7	41
250	Different negative priming impairments in schizophrenia and subgroups of obsessive-compulsive disorder. <i>Psychological Medicine</i> , 2002, 32, 459-468.	2.7	27
251	Moclobemide Response in Depressed Patients: Association Study with a Functional Polymorphism in the Monoamine Oxidase A Promoter. <i>Pharmacopsychiatry</i> , 2002, 35, 157-158.	1.7	41
252	Further evidence for age of onset being an indicator for severity in bipolar disorder. <i>Journal of Affective Disorders</i> , 2002, 68, 343-345.	2.0	43

#	ARTICLE	IF	CITATIONS
253	Association between a polymorphism in the pseudoautosomal X-linked gene SYBL1 and bipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 74-78.	2.4	25
254	Association study between two variants in the DOPA decarboxylase gene in bipolar and unipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 519-522.	2.4	19
255	Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?. <i>European Psychiatry</i> , 2001, 16, 71-74.	0.1	8
256	Major psychoses symptomatology: factor analysis of 2241 psychotic subjects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 193-198.	1.8	38
257	No evidence for linkage by transmission disequilibrium test analysis of microsatellite marker D22S278 and schizophrenia in a Palestinian Arab and in a German population. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 328-331.	2.4	3
258	Caught in the trio trap? Potential selection bias inherent to association studies using parent-offspring trios. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 351-353.	2.4	21
259	Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. <i>American Journal of Medical Genetics Part A</i> , 2001, 105, 498-501.	2.4	56
260	A possible susceptibility locus for bipolar affective disorder in chromosomal region 10q25-q26. <i>Molecular Psychiatry</i> , 2001, 6, 342-349.	4.1	50
261	A genome screen for genes predisposing to bipolar affective disorder detects a new susceptibility locus on 8q. <i>Human Molecular Genetics</i> , 2001, 10, 2933-2944.	1.4	126
262	Familial occurrence of tardive dyskinesia. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 375-9.	2.2	79
263	Investigation of the human serotonin 6 (5-HT ₆) receptor gene in bipolar affective disorder and schizophrenia. , 2000, 96, 217-221.		62
264	Association study of the tryptophan hydroxylase gene and bipolar affective disorder using family-based internal controls. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 310-311.	2.4	17
265	Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 801-803.	2.4	168
266	Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). <i>Molecular Psychiatry</i> , 2000, 5, 275-282.	4.1	106
267	Dopamine D3 receptor variant and tardive dyskinesia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2000, 250, 31-35.	1.8	60
268	Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 544-558.	0.9	137
269	Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuroscience Letters</i> , 2000, 289, 147-151.	1.0	63
270	Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 801-803.	2.4	1

#	ARTICLE	IF	CITATIONS
271	Apolipoprotein E ε4 and clinical phenotype in schizophrenia. <i>Lancet, The</i> , 1997, 350, 1857-1858.	6.3	8